EV/EBITDA Multiple: Lipocine Corp (LPCN)

Corporate company logo of lipocine.com (LPCN)

Successful tests of liver pathology treatments are already priced into the quotes of Lipocine Inc. (LPCN), while new agreements with industry behemoths are expected later. The EV/EBITDA market trend, which currently stands at 0.00, reflects the price action of LPCN. Lipocine Inc. (LPCN) is developing tablet alternatives to injections via the Lip's system, creating a barrier for competitors. However, certification challenges for hormonal agents and patent disputes remain possible.

LPCN (Lipocine Inc) Enterprise Value to Operating Income Before Depreciation Ratio history from 11/23/2025 to 11/12/2026

lipocine.com (LPCN) - metric breakdowns and financial figures

- market price and analyst price targets:
Price Chart Lipocine Corp|LPCN - Consensus Target
- company stock exchange capitalization indicators:
Market Capitalization Lipocine Corporation|LPCN - Total Enterprise Value
- issuer book value statistics:
Accounting Value per Share Lipocine|LPCN - Total Net Assets|Market Capitalization to Book Value Ratio lipocine.com|LPCN - Company Total Assets
- debt and liquidity data:
Total Debt to Capital Lipocine Inc.|LPCN - Long-Term Debt to Equity|Short-Term Debt to Equity Lipocine|LPCN - Company Cumulative Debt|Debt to Book Capitalization Ratio Lipocine Corporation|LPCN - Company Long-Term Debt|Company Short-Term Debts Lipocine|Quick Liquidity lipocine.com
- net income and valuation multiples indicators:
LPCN - Net Financial Result|Expected Profit Lipocine Inc.|LPCN - Price to Earnings Ratio|Future Price to Earnings Lipocine Inc.|LPCN - Price/Earnings to Growth Ratio|EV/EBITDA Multiple Lipocine Corporation|LPCN - Operating income before deduction of amortization|Earnings per share for the last twelve months Lipocine|LPCN - Earnings per one share for the last 12 months|Year-over-year earnings per share growth for the last twelve months lipocine.com|LPCN - Earnings per share growth rate in current year|Earnings growth forecast for next year Lipocine Inc.
Initial company analysis:LPCN (Lipocine Corp)
Product sample of Lipocine

This indicator determines the total enterprise value relative to its operating profit before depreciation, taxes, and interest, allowing for an assessment of the real value of assets accounting for the debt load. By analyzing the EV/EBITDA multiple, an investor can compare the market price of Lipocine Inc. (LPCN) with the efficiency of its transition toward metabolic and CNS therapies during the clinical trial period.

Who Lipocine Inc. competes with

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Ascendis Pharma Inc. ASND|MDGL - Enterprise Value to EBITDA Ratio|Corcept Therapeutics - EV/EBITDA Multiple|Company Value to EBITDA rhythmtx.com|AKRO (Akero) - Enterprise Value to EBITDA Ratio|MTSR: Enterprise Value to Operating Income Before Depreciation Ratio|MLTX (MoonLake Pharma) - EV/EBITDA Multiple|EV/EBITDA Multiple Crinetics Corp|EV/EBITDA Multiple NAMS|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization SLNO (soleno.life)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Amicus Therapeutics, Inc. FOLD|89bio Inc (ETNB) - Company Value to EBITDA|AGIO - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|GPCR: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|MDXG: EV/EBITDA Multiple|RZLT - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Lexicon Pharmaceuticals, Inc.|MBX Biosciences, Inc. (MBX) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Altimmune Corp (ALT)|Enterprise Value to EBITDA Ratio Aardvark Pharma AARD|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Sagimet Biosciences SGMT|bioagelabs.com - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Biomea Fusion - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Quince Therapeutics QNCX|Fractyl (GUTS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio VTVT (vTv Therapeutics)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Agape ATP Corp|Company Value to EBITDA Pluri Inc PLUR|EV/EBITDA Multiple SYBX|Enterprise Value to EBITDA Ratio matinasbiopharma.com MTNB|EV/EBITDA Multiple SPRB (Spruce Biosciences)|Total Company Value to Operating Income Before Depreciation Ratio Galecto Corporation (GLTO)|CTCX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|LUMO (lumos-pharma.com) - Enterprise Value to Operating Income Before Depreciation|ONVO: EV/EBITDA Multiple|Company Value to EBITDA Radius Recycling Inc. (RDUS)